News

A matched case-control study of nearly 100 women details the reduced effect of anti-obesity medications in those with a history of breast cancer and aromatase inhibitor use.

This data indicates that public health officials may need to implement measures to both help prevent and detect domestic violence in order to reduce the associated effects.

New CDC survey data show an estimated 47 million adults in the US have ever been diagnosed with depression, with clear disparities based on demographics and regions.

A phase 4 trial of men with hypogonadism in the US offers an overview of the potential risk of major cardiovascular events associated with use of testosterone replacement therapy.

With a pair of novel drugs seeking FDA approval for the common skin infection, the agency stresses avoiding misleading products currently on the market.

The US Food and Drug Administration (FDA) approved linaclotide earlier this month for the treatment of patients with functional constipation aged 6-17 years.

Based on the results of 2 studies, lower birthweight was associated with younger age, lower prevalence of obesity, and fewer individuals with a family history of T2D.

Future studies of socioeconomic factors and environmental elements contributing may help to further explain the causes of food allergies and inform targeted interventions and management.

All primary endpoints evaluating pharmacokinetics were achieved and immunogenicity and safety were comparable across treatment arms.

Amgevita and Idacio exhibited higher rates than methotrexate at both week 24 and week 52 suggesting adalimumab biosimilars provided superior treatment persistence among patients with moderate-to-severe psoriasis.

An analysis of US adults suggests MAFLD affects the Hispanic population at a higher prevalence relative to Black adults and White adults.

This research was conducted to examine the end-of-life trajectories of older adults and investigate distribution over gender, age, and causes of mortality.

"Our research is unique in its attempt to describe a high-need, high-cost patient population who might benefit from increased monitoring or intervention," Dr. Ann Cameron says.

A geriatric expert, Presley provides a poignant point-of-view on the need for a multidisciplinary approach to patient care, as well as advances in treatment that include targeted therapies.

The race-neutral model resulted in worse calibration, NPV, and false-negative rates among racial and ethnic minority subgroups compared to non-Hispanic White participants.

An analysis of survey data from more than 50 health care workers in Massachusetts offers insight into the effects of the COVID-19 pandemic

This new research may help clinicians in their guidance of patients with T21, though the data may require future studies to help examine immune parameters of the clinical outcomes.

In the phase 2b ORIGIN trial, atacicept resulted in a statistically significant reduction in mean proteinuria compared to baseline at week 24.

On June 15, 2023, Bristol Myers Squibb announced the FDA approved an updated label for mavacamten (Camzyos) to reflect the agent's ability to reduce the need or eligibility for septal reduction therapy in patients with obstructive HCM based on VALOR-HCM.

Research presented at ENDO 2023 suggests a high number of adults in the United States with normal BMI still have obesity.

The investigation of 11 alternative DMARD therapies in combination with methotrexate shows a lack of economic attractiveness compared with the standard of care.

In the latest episode of New Insight, Veeral Sheth, MD sat down with Cedric Francois, MD, PhD, to discuss the recent FDA approval of pegcetacoplan (SYFOVRE™), the interplay between being a clinician and corporate executive, and how the retina landscape may change in the coming years.

Criner and colleagues concluded that the 5-year results from the EMPROVE trial demonstrated that Spiration Valve System (SVS) treatment was safe and durable, effectively improving lung function in patients with emphysema

An analysis of data from the CLEAR Outcomes trial presented at ENDO 2023 suggests use of the non-statin lipid-lowering agent provided cardiovascular risk reduction comparable to statin therapy for each 1.0 mmol/L reduction in LDL-C.

There were no new safety signals identified from the COMMAND trial.

This endocrine case report from Brady Pregerson, KMD, features a woman in her mid-30s with a history of cerebral astrocytoma status post radiation therapy presenting with generalized weakness, a gradual onset generalized headache, and excessive thirst. Can you determine the correct diagnosis?

"High-risk patients are more likely to experience comorbid conditions and are more likely to use COPD medications and oxygen, reflecting a higher disease burden," Dr. Ann Cameron explains.

Statistically significant reductions in erythema, scaling, thickness, and overall target plaque scores were observed in both treatment regimens.